

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
9 September 2005 (09.09.2005)

PCT

(10) International Publication Number
WO 2005/081897 A2

(51) International Patent Classification: **Not classified**

(21) International Application Number:
PCT/US2005/005381

(22) International Filing Date: 18 February 2005 (18.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/783,699 20 February 2004 (20.02.2004) US

(71) Applicant (for all designated States except US): **AC IMMUNE SA** [CH/CH]; EPFL - PSE Building B, CH-1015 Lausanne (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **NICOLAU, Yves, Claude** [FR/US]; 166 Greenwood Street, Newton, Massachusetts 02459 (US). **ELISEEV, Alexey** [US/US]; 419

Washington Street, #1, Brookline, Massachusetts 02446 (US). **LEHN, Jean-Marie** [FR/FR]; 6, rue des Pontonniers, F-67000 Strasbourg (FR).



(74) Agents: **PRATT, John, S.** et al.; Kilpatrick Stockton LLP, 1100 Peachtree Street, Suite 2800, Atlanta, GA 30309 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: METHODS AND COMPOSITIONS COMPRISING NON-PEPTIDE SMALL MOLECULES THAT SOLUBILIZE BETA AMYLOID PEPTIDE FIBER



(57) Abstract: The present invention comprises novel compositions and methods for the treatment of neurological diseases associated with beta amyloid peptide. In particular, the present invention is directed to AB fiber solubilization, for the treatment of amyloid-associated diseases such as Alzheimer's disease, and is described herein as being achieved by using small molecules binding to AB fiber. The present invention further comprises novel methods of designing and screening compositions for the treatment of neurological disease wherein the design aspect comprises the modeling of molecular scaffolds having optimal structural characteristics that enable the development of small molecule compositions of non-peptide nature having desirable solubilization effects on amyloid plaques. In one embodiment, the design of the compounds comprises a molecular structure with three chemical domains that include a melatonin-like domain, a nicotine-like domain and a peptide-like domain for binding to AB.



GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.